Motor matters: tackling heterogeneity of Parkinson's disease in functional MRI studies

PLoS One. 2013;8(2):e56133. doi: 10.1371/journal.pone.0056133. Epub 2013 Feb 13.

Abstract

To tackle the heterogeneity of Parkinson's disease symptoms, most functional imaging studies tend to select a uniform group of subjects. We hypothesize that more profound considerations are needed to account for intra/inter-subject clinical variability and possibly for differing pathophysiological processes. Twelve patients were investigated using functional magnetic resonance imaging during visually-guided finger tapping. To account for disease heterogeneity, the motor score and individual symptom scores from the Unified Parkinson's Disease Rating Scale (UPDRS-III) were utilized in the group-level model using two approaches either as the explanatory variable or as the effect of interest. Employment of the UPDRS-III score and symptom scores was systematically tested on the resulting group response to the levodopa challenge, which further accentuated the diversity of the diseased state of participants. Statistics revealed a bilateral group response to levodopa in the basal ganglia. Interestingly, systematic incorporation of individual motor aspects of the disease in the modelling amended the resulting activity patterns conspicuously, evidencing a manifold amount of explained variability by the particular score. In conclusion, the severity of clinical symptoms expressed in the UPDRS-III scores should be considered in the analysis to attain unbiased statistics, draw reliable conclusions and allow for comparisons between research groups studying Parkinson's disease using functional magnetic resonance imaging.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Antiparkinson Agents / administration & dosage
  • Basal Ganglia / drug effects
  • Basal Ganglia / physiopathology
  • Carbidopa / administration & dosage
  • Disability Evaluation
  • Humans
  • Levodopa / administration & dosage
  • Magnetic Resonance Imaging / methods*
  • Male
  • Middle Aged
  • Parkinson Disease / diagnosis*
  • Parkinson Disease / drug therapy
  • Parkinson Disease / physiopathology*
  • Psychomotor Performance / drug effects
  • Psychomotor Performance / physiology*
  • Reproducibility of Results
  • Sensitivity and Specificity
  • Severity of Illness Index

Substances

  • Antiparkinson Agents
  • Levodopa
  • Carbidopa

Grants and funding

This work was supported by the Czech Science Foundation, grant project 309/09/1145; by the Czech Ministry of Health, IGA MZ ČR NT12282-5/2011, IGA MZ ČR NT12288-5/2011, IGA MZ ČR NT 11331-6/2010; by the Czech Ministry of Education, research project MŠM 0021620849; by the Charles University in Prague, research project PRVOUK-P26/LF1/4; and by the Czech Technical University in Prague, grant project SGS10/279/OHK3/3T/13. Štefan Holiga has been supported by a stipend from the International Max Planck Research School on Neuroscience of Communication: Function, Structure, and Plasticity (IMPRS NeuroCom). Matthias Schroeter has been supported by LIFE – Leipzig Research Center for Civilization Diseases at the University of Leipzig - funded by European Union, European Regional Development Fund and by Free State of Saxony within the framework of the excellence initiative, and by the German Consortium for Frontotemporal Lobar Degeneration, funded by the German Federal Ministry of Education and Research. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.